Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Zeldox ziprasidone dopamine D2 and serotonin 5HT2 receptor antagonist and serotonin receptor agonist regulatory update

January 2, 2001 8:00 AM UTC

PFE said Sweden agreed to delay EU review of its MAA for Zeldox to treat schizophrenia to consider additional data and analyses that also have been submitted to the FDA for review, as well as data fro...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article